WuXi AppTec Executive and Leadership Team

Ge Li, the Chief Executive Officer at WuXi AppTec, directs the overarching corporate strategy and long-term vision for the global research and manufacturing platform. By fostering an open-access ecosystem, the Chief Executive Officer enables pharmaceutical and biotech companies to accelerate the discovery of small molecule drugs and advanced therapies. Ge Li maintains rigorous oversight of the six core business segments, ensuring that the organization remains at the forefront of synthetic molecular modalities. This leadership role involves constant engagement with the Board to align operational capabilities with international market demands. Through the promotion of integrated project solutions, the Chief Executive Officer drives the company toward its mission of making drug development more efficient. Ultimately, the strategic direction provided by Li ensures that the firm remains a critical partner for innovators across the People's Republic of China, the United States, and Europe.

Minzhang Chen, the Co-Chief Executive Officer of WuXi AppTec at WuXi AppTec, manages the complex manufacturing and development operations that support global drug commercialization. Focusing on the WuXi Chemistry segment, the Co-Chief Executive Officer of WuXi AppTec optimizes synthetic processes for oligonucleotides, peptides, and complex conjugates. Minzhang Chen coordinates with internal research teams to ensure seamless transitions from candidate selection to large-scale clinical production. This role requires deep technical expertise to maintain high quality standards across international facilities. By streamlining manufacturing workflows, the Co-Chief Executive Officer of WuXi AppTec enhances the speed-to-market for critical therapeutic assets. Chen also collaborates with other C-suite leaders to align operational capacity with the evolving needs of the global pharmaceutical industry. Through this focused leadership, the firm achieves consistent growth in its contract development and manufacturing organization services, providing essential support for diverse molecular modalities.

Steve Yang, the Co-Chief Executive Officer at WuXi AppTec, oversees the biology services and integrated project solutions that span from target discovery to clinical entry. The Co-Chief Executive Officer directs the expansion of the WuXi Biology and WuXi DDSU segments, ensuring that research capabilities meet the sophisticated requirements of modern drug development. Steve Yang manages the strategic integration of stand-alone projects into the broader company platform, facilitating a cohesive approach to candidate selection. This leadership position involves constant interaction with global research partners to identify emerging trends in advanced therapies. By optimizing the research pipeline, the Co-Chief Executive Officer improves the efficiency of early-stage drug discovery. Yang also works closely with the executive team to ensure that scientific advancements translate into tangible business outcomes. Through this focus on innovation, the firm maintains a competitive edge in the international market, supporting the development of life-saving treatments for patients worldwide.

Florence Shi, the Senior Vice President, Chief Financial Officer at WuXi AppTec, directs the financial strategy, capital allocation, and fiscal reporting for the entire organization. The Senior Vice President, Chief Financial Officer manages the financial health of the six business segments, ensuring that resources are effectively deployed to support research and manufacturing growth. Florence Shi oversees investor relations and ensures transparency in all financial disclosures to stakeholders. This role involves rigorous analysis of market trends to inform long-term investment decisions and risk management strategies. By maintaining a robust financial framework, the Senior Vice President, Chief Financial Officer supports the company's ability to scale its global operations and invest in advanced therapeutic technologies. Shi also works closely with the executive team to ensure that financial performance aligns with the overarching mission of the firm. Through this disciplined approach, the company secures the necessary capital to continue its expansion across international markets.

Zhaohui Zhang, the Executive Vice President & Chief Operating Officer (China) at WuXi AppTec, manages the daily operational execution and infrastructure development within the domestic market. The Executive Vice President & Chief Operating Officer (China) ensures that all laboratory and manufacturing facilities operate at peak efficiency to support the company's diverse service segments. Zhaohui Zhang coordinates cross-functional teams to maintain high standards of service delivery for clients across the People's Republic of China. This role involves overseeing resource allocation and process optimization to support the rapid scaling of research projects. By driving operational excellence, the Executive Vice President & Chief Operating Officer (China) enables the firm to meet the complex demands of drug discovery and development. Zhang also collaborates with regional leadership to ensure that domestic operations remain aligned with the global strategic goals of the organization. Through this focus on operational stability, the firm sustains its position as a leader in the regional pharmaceutical services sector.

Erich Koch, the Chief Operations Officer at WuXi AppTec, manages the global operational infrastructure and supply chain logistics that underpin the company's service delivery. The Chief Operations Officer ensures that the international network of facilities maintains consistent quality and compliance standards across all regions. Erich Koch coordinates the integration of operational workflows to support the WuXi Testing and WuXi ATU segments. This role involves optimizing cross-border logistics to facilitate the seamless movement of research materials and clinical samples. By enhancing operational agility, the Chief Operations Officer enables the firm to respond rapidly to the needs of global pharmaceutical partners. Koch also collaborates with regional operations leaders to ensure that the company's service capacity scales in line with market demand. Through this focus on operational efficiency, the firm maintains its reputation for reliability and excellence in the international drug development landscape, supporting complex projects from discovery to commercialization.

Xiaozhong Liu, the Executive VP & Head of the Strategic Project Office at WuXi AppTec, directs the planning and execution of high-priority initiatives that drive the company's long-term growth. The Executive VP & Head of the Strategic Project Office manages the cross-segment coordination required to launch new service offerings and expand into emerging therapeutic areas. Xiaozhong Liu oversees the implementation of complex projects that require alignment across the WuXi Chemistry, Biology, and Testing divisions. This role involves identifying strategic opportunities for business development and ensuring that internal resources are focused on the most impactful initiatives. By managing the strategic project pipeline, the Executive VP & Head of the Strategic Project Office ensures that the firm remains adaptable to the rapidly changing pharmaceutical environment. Liu also works with the executive team to evaluate the feasibility of new market entries and service expansions. Through this leadership, the company successfully executes its vision for continuous innovation and market leadership.